全文获取类型
收费全文 | 961822篇 |
免费 | 48578篇 |
国内免费 | 1323篇 |
专业分类
耳鼻咽喉 | 12969篇 |
儿科学 | 32843篇 |
妇产科学 | 27394篇 |
基础医学 | 151365篇 |
口腔科学 | 24523篇 |
临床医学 | 82335篇 |
内科学 | 176801篇 |
皮肤病学 | 21525篇 |
神经病学 | 64588篇 |
特种医学 | 39593篇 |
外国民族医学 | 190篇 |
外科学 | 144762篇 |
综合类 | 16008篇 |
现状与发展 | 3篇 |
一般理论 | 263篇 |
预防医学 | 70617篇 |
眼科学 | 21950篇 |
药学 | 71315篇 |
3篇 | |
中国医学 | 1972篇 |
肿瘤学 | 50704篇 |
出版年
2018年 | 12438篇 |
2017年 | 10328篇 |
2016年 | 10826篇 |
2015年 | 13143篇 |
2014年 | 15364篇 |
2013年 | 20666篇 |
2012年 | 33174篇 |
2011年 | 30505篇 |
2010年 | 17690篇 |
2009年 | 17527篇 |
2008年 | 25774篇 |
2007年 | 28871篇 |
2006年 | 28529篇 |
2005年 | 35197篇 |
2004年 | 35829篇 |
2003年 | 30707篇 |
2002年 | 25161篇 |
2001年 | 37829篇 |
2000年 | 36666篇 |
1999年 | 33858篇 |
1998年 | 8407篇 |
1997年 | 7155篇 |
1996年 | 7102篇 |
1995年 | 6792篇 |
1992年 | 27141篇 |
1991年 | 28396篇 |
1990年 | 28443篇 |
1989年 | 27836篇 |
1988年 | 25509篇 |
1987年 | 24988篇 |
1986年 | 23568篇 |
1985年 | 22355篇 |
1984年 | 16321篇 |
1983年 | 13842篇 |
1982年 | 7218篇 |
1981年 | 6311篇 |
1979年 | 15926篇 |
1978年 | 11078篇 |
1977年 | 9003篇 |
1976年 | 8884篇 |
1975年 | 11004篇 |
1974年 | 12752篇 |
1973年 | 12277篇 |
1972年 | 11511篇 |
1971年 | 11070篇 |
1970年 | 10437篇 |
1969年 | 9738篇 |
1968年 | 9239篇 |
1967年 | 8476篇 |
1966年 | 7519篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
Journal of Behavioral Medicine - Evidence supports the use of graphic warnings to educate the public about the health harms of smoking and suggests warnings eliciting negative emotional responses... 相似文献
3.
The adrenal cortex gives rise to a biologically heterogenous group of neoplasms, each with a distinct morphology, antigen expression and molecular profile. Adrenal cortical adenomas have excellent prognosis and are usually cured by surgical resection alone, while adrenal cortical carcinomas are very aggressive tumors with a poor prognosis regardless of therapy. These tumors are rare and often challenging for a pathologist to diagnose, as significant overlap exists between benign and malignant lesions in some cases. In this review, we attempt to summarize most important histologic and clinical features of adrenal cortical adenomas and carcinomas, clarify the use of different grading systems, the use of special stains and the differential diagnosis for practicing pathologists. Most relevant hereditary syndromes associated with adrenal cortical tumors are listed. Updates in molecular alterations in adrenal cortical neoplasms and hyperplastic diseases as well as their clinical significance and potential therapeutic implications are also discussed. 相似文献
4.
5.
6.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
7.
8.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献
9.
10.